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Objective: To evaluate the efficacy of Kivia powder on supporting overall gut health through the relief of the
discomfort of occasional constipation.
Design: Randomized, double-blind, placebo-controlled, parallel-group trial.
Interventions: The investigational product for this study was Kivia powder (Vital Food Processors Ltd., Auckland,
New Zealand), containing the active ingredient Zyactinase™, 5.5 g taken daily for four weeks.
Results: One hundred thirty-eight subjects reporting occasional constipation were screened and 87 were randomized
to placebo (n = 44) and product (n = 43). Bowel movement frequency, as measured by both average daily spontaneous
bowel movements (SBM) and complete spontaneous bowel movements (CSBM), were the same in both groups at
baseline. There were significant increases in spontaneous bowel movements at week 1 (p = 0.001), week 2 (p = 0.001),
week 3 (p = 0.000), and week 4 (p = 0.000) compared to baseline. SBM demonstrated significant differences between the
treatment group and the placebo group at week 3 (p = 0.000), and week 4 (p = 0.020). The treatment group
demonstrated a significantly higher rate of SBM at week 3 (p = 000) and from baseline to week 4 (p = 0.019). Significant
increases in complete spontaneous bowel movements were observed at week 1 (p = 0.000), week 2 (p = 0.000), week 3
(p = 0.000), and week 4 (p = 0.000) compared to baseline. Moreover, CSBM was significantly higher for the treatment
group compared to placebo at week 2 (p = 0.001). The change in average daily CSBM from baseline to week 2 was
significantly higher in the treatment group than in the placebo group (p = 0.004).
Abdominal discomfort or pain demonstrated significant differences between groups at week 1 (p = 0.044) and week 3
(p = 0.026). Flatulence was significantly lower for active group compared to placebo at week 2 (p = 0.047) and week 3
(p = 0.023). The number of bowel movements associated with urgency was significantly lower in the treatment group
compared to the placebo group at week 3 (p = 0.048). In addition, it was decreased from baseline to week 1 (p = 0.040)
and from baseline to week 3 (p = 0.024) in the treatment group, while the placebo group did not report any reductions
in bowel urgency. Bowel movements in the treatment arm were significantly smoother and softer by week 2 (p = 0.020)
and week 3 (p = 0.041).
Conclusions: Treatment with Kivia powder, an extract of kiwifruit containing Zyactinase™, for four weeks was well
tolerated and more effective than placebo in gently enhancing bowel movement frequency and reducing abdominal
pain and flatulence in subjects with occasional constipation.
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According to the American Gastroenterological Associ-
ation, among healthy people, the frequency of bowel move-
ments may vary from three movements per week to three
daily. Constipation may be suspected if there is difficulty or
pain when passing a hardened stool or if greater than three
days pass between bowel movements. Occasional constipa-
tion is common and occurs in most people at some point.
In some typically healthy individuals, evacuating the bowels
is difficult at times, even in the absence of any physical or
physiological symptoms. Neurological, psychological, or
psychosomatic problems may be the cause in some indi-
viduals. Contributing factors to constipation include gen-
der (being female), age (being older), diet and lifestyle
choices, use of certain medications, and bowel habits.
In North America, constipation prevalence has been
quoted at 1.9–27.2% [1,2], with the majority of the insti-
tutionalized elderly reporting laxative use on a daily
basis [3] and women reporting constipation more fre-
quently than men. In the United States, constipation is
one of the top five outpatient gastrointestinal diagnoses
[4], costing approximately $7,500 (US dollars) for diag-
nosis and treatment provision [5].
For the prevention and treatment of occasional consti-
pation, the American Gastroenterological Association
recommends eating a well-balanced diet, including bran,
whole-wheat grains, and fresh fruit and vegetables, as
well as drinking plenty of fluids and exercising regularly.
It also recommends setting time aside for undisturbed
visits to the toilet and not ignoring the urge to have a
bowel movement. If these suggestions are not adequate,
laxatives may be recommended by the physician. Over-
the-counter laxatives for treatment of occasional consti-
pation include bulk-forming laxatives, stimulants, stool
softeners, lubricants, and osmotics.
Several herbal or natural products have been used trad-
itionally or are of interest for constipation, including aloe,
psyllium, probiotics, and rhubarb [6-8]. Actinidia, a genus
of plants cultivated mainly for its fruit (kiwifruit), grows in
various countries. Major producers of kiwifruit include
Italy, New Zealand, Chile, and France. The fruit of the kiwi
is of interest for gastrointestinal health, based on anec-
dotal data surrounding its cysteine protease constituent,
actinidin. Preliminary published [9] and unpublished data
suggest that use of kiwifruit decreased constipation in eld-
erly patients. Rush et. al. reported the use of kiwifruit as
laxative, including the increased frequency and ease of
defecation, stool bulk, and softness in elderly patients [10].
Chan et. al. also investigated the benefits of kiwifruit in
treating constipation in Chinese patients. The dietary fiber
present in large amount in kiwifruit contributes to its laxa-
tive properties [11]. It has high water-containing capacity
suggesting possible effect in fecal bulking and enhance-
ment of laxation [12]. Several other clinical studies haveexplored the ability of zyactinase in alleviating constipa-
tion [13].
Kivia powder containing Zyactinase™ is a freeze-dried
powder from kiwifruit (Actinidia deliciosa var. deliciosa
(C.F. Liang and A.R. Ferguson), containing the enzyme
actinidin, plant polyphenols, dietary fiber, carbohydrates,
and oligosaccharides. Actinidin, an enzyme which can di-
gest proteins, has been shown in vitro to dislodge meat
boluses [14] and enhance gastric protein digestion [15,16].
In addition to the digestive enhancing action of actinidin,
galactoglucomannan, a type of oligosaccharide, has also
been isolated from kiwifruit [17]. It has been hypothesized
that the oligosaccharides found in kiwifruit and Zyactinase™
may act as prebiotics in the human gut stimulating the
growth of beneficial bacteria. Actinidin also aids in laxation
by stimulating the receptors of the colon thus increasing
colon motility [18].
Although the gastrointestinal effects of kiwifruit have
been investigated in laboratory studies, there is a lack of
human research in the area of constipation. This ran-
domized, double-blind, placebo-controlled study was
conducted to provide valuable data to support or refute
the proposed effects of Kivia powder from kiwifruit on
the improvement of gastrointestinal function in subjects
with occasional constipation.Methods
Investigational product
The investigational product for this study was Kivia pow-
der (Vital Foods Processors Ltd, Auckland, New Zealand),
containing the active ingredient Zyactinase™, at a dose of
5.5g per sachet. Kivia powder is an extract of kiwifruit
(Actinidia deliciosa var. deliciosa (C.F. Liang and A.R.
Ferguson)) prepared by a proprietary freeze-drying tech-
nique without solvents or extraction. The placebo was a
combination of inactive components, including lemon
powder, vital spirulina, citric acid, fructose, sucralose, and
tropical flavor. Both products were provided by the spon-
sor, and both were GMP certified (batch numbers BN9460
and BN9465, for the product and placebo, respectively).
The sachets were produced as identical packages. The
daily dose of both groups was one sachet dissolved in cold
water with breakfast. The sponsor also provided a rescue
medication (bisacodyl rectal suppository, 10mg) for use
during the study. Other over-the-counter products for
constipation were not allowed during the course of the
study. Also excluded were oral aloe vera and garlic supple-
ments. Birth control hormonal agents and acetaminophen
were allowed during the study.
Subjects
Subjects included in the study were healthy adults, be-
tween 18 and 65 years of age and with a body mass
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symptoms consistent with occasional constipation; these
included at least two of the following occurring during
the two-week run-in period: three or fewer defecations
per week, straining during at least 25% of defecations,
lumpy or hard stools in at least 25% of defecations, a sen-
sation of incomplete evacuation for at least 25% of defeca-
tions, a sensation of anorectal obstruction or blockage for
at least 25% of defecations, and manual maneuvers to fa-
cilitate at least 25% of defecations (e.g., digital evacuation,
support of the pelvic floor). It is important to note that
this was a study of dietary supplement and not a drug,
hence any subject with a disease state related to the thera-
peutic area of the study product (including Irritable Bowel
Syndrome (IBS)) was excluded from the study. Subjects
with any significant gastrointestinal condition that would
potentially interfere with the evaluation of the study prod-
uct, including but not limited to, inflammatory bowel dis-
ease (ulcerative colitis or Crohn’s) were also excluded.
Additional exclusion criteria included a history of perfor-
ation of the stomach or intestines, gastroparesis, or clinic-
ally important lactose intolerance, known allergy or
sensitivity to kiwi fruit, or a recent (within two weeks of
visit 1, week -1) episode of acute gastrointestinal illness
such as nausea, vomiting, or diarrhea were excluded. Sub-
jects were also required to be willing to maintain his or
her habitual food and beverage intake and physical activity
patterns throughout the study period. The subjects were
judged by the investigator to be in general good health on
the basis of their medical histories. Informed consents were
signed and returned prior to dispensing any study product.
In addition, any concomitant medications and/or dietary
supplements, which affected the GI tract, were prohibited
during the study. Subjects were recruited from the com-
munity, including through online recruiting (Craigslist),
advertising, and available databases. Subjects were phone-
screened prior to scheduling a screening visit.Study design
This was a randomized, double-blind, placebo-controlled,
parallel-design study, with 87 men and women taking the
study product daily for four weeks. An interim analysis on
the primary endpoint was performed after completion by
the first 50 subjects. It was determined that additional
subjects would be necessary to reach statistical signifi-
cance. Simple randomization was prepared using a com-
puter program based on the atmospheric noise method,
and sequential assignment was used to determine group
allocation. Group allocation was placed in individual num-
bered envelopes, to maintain blinding of all individuals.
The study was double-blind, using identical sachets. Sub-
jects, clinical staff, data management staff, and statistical
analysis staff were unaware of the study group. The studywas conducted at the Staywell Research clinical research
site located in Northridge, CA, and Medicus Research was
the contract research organization (CRO) for this study.
Subjects were recruited from the community and assigned
to treatment by the research site. Institutional review board
(IRB) approval was received (Copernicus Group IRB, Cary,
NC) prior to the initiation of any study-related activities
(approved August 2010, first patient recruited September
2010, last patient recruited October 2011). The study flow-
chart is provided in Figure 1. Five subjects did not
complete the study, because they were lost to follow-up
(the patients stopped coming in and no reason was pro-
vided). The trial concluded following randomization and
completion of the required number of subjects.
At screening (visit 1, day −14), subjects underwent the
informed consent process and were screened for the
presence of all of the inclusion criteria and the absence
of all of the exclusion criteria. This screening process in-
cluded a detailed medical history, vital signs, anthropo-
metric measures, demographic data, and urine collection
for pregnancy (if applicable). If subjects were deemed
eligible, they were asked to stop the use of any medica-
tions for constipation and to begin keeping a daily diary
of their bowel habits.
At baseline (visit 2, day 0), eligibility was reconfirmed
with regard to medical history and concomitant medi-
cation history. If the subjects met all of the inclusion
criteria and none of the exclusion criteria, they were
randomized based on an envelope containing the ap-
propriate group placement (based on a previous
randomization scheme). At this visit, the subjects were
instructed verbally on the following: the use and storage
of the study product; the number, dates, and times of
visits; any study procedures; daytime and emergency
contact information; completion of the study diary; and
returning unused product.
At week 2 (visit 3, day 14), subjects returned to the study
site. Medical histories and medication histories were
reviewed and updated. At this time, completed diaries and
unused product were returned and obligations were
discussed. Subjects were reminded verbally on the use and
storage of the study product, as well as the number, dates,
and times of visits, any study procedures, daytime and
emergency contact information, completion of the study
diary, and returning unused product.
At week 4 (visit 4, day 30), subjects returned to the study
site. Medical histories and medication histories were
reviewed and updated. At this time, completed diaries and
unused product were returned. This visit included vital
signs and anthropometric measures.
Subjects were called twice by the study staff in order
to improve compliance and completion of the study
diary, to remind subjects of their obligations and up-
coming visits, and to discuss any medical issues.
Figure 1 Study procedure flowchart.
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This study was designed to determine the efficacy of
Kivia powder on the improvement of gut health parame-
ters in subjects with occasional constipation.
Primary endpoint
The primary endpoint of this study was bowel movement
frequency. Bowel movement frequency is a parameter
used to assess how often an individual have his/her bowel
movement and is reported as a daily average by week. The
numbers of spontaneous bowel movements and complete
spontaneous bowel movements were investigated. Spon-
taneous bowel movement (SBM) is defined as a stool not
induced by rescue medication while complete spontan-
eous bowel movement (CSBM) is SBM associated with a
sensation of complete evacuation. In addition, a complete
spontaneous bowel is a bowel movement during which
the subject answered “yes” to the question “Have you
completely emptied your bowel?”.
Secondary endpoints
The secondary objective was to determine the efficacy of
Kivia powder compared to placebo on gut health, based on
diary information. Endpoints included stool form (Bristol
Stool Scale), bowel urgency (yes/no), abdominal bloating
(0 = none, 1 =mild, 2 =moderate, 3 = intense, 4 = severe),
abdominal discomfort or pain (0 = none, 1 =mild, 2 =mod-
erate, 3 = intense, 4 = severe), satisfaction with bowel habits
(0 = a great deal satisfied, 1 = a good deal satisfied, 2 =
moderately satisfied, 3 = hardly satisfied, 4 = not satisfied
at all), flatulence (0 = none, 1 =mild, 2 =moderate, 3 =
intense, 4 = severe), and burping (0 = none, 1 =mild, 2 =
moderate, 3 = intense, 4 = severe). The Bristol Stool Scale is
used to classify the form of feces into categories (type 1 =
separate hard lumps, like nuts, type 2 = sausage-shaped but
lumpy, type 3 = like a sausage with cracks on surface, type
4 = like a sausage or snake, smooth and soft, type 5 =
soft blobs with clear-cut edges and passed easily, type
6 = fluffy pieces with ragged edges, a mushy stool, type
7 = watery, no solid pieces, entirely liquid) [14].
Tertiary endpoints
The tertiary objective of the study was to determine the
efficacy of Kivia powder compared to placebo on the use
of rescue medication.
Quaternary endpoints
The quaternary objective of the study was to determine
the safety of Kivia powder compared to placebo. This
was based on an adverse event assessment.
Statistics
A modified per-protocol analysis was performed, includ-
ing all subjects who had at least one poststudy product
Table 1 Demographic and baseline characteristics




Age (Mean) 41 ± 14 38 ± 14 0.236
Age (Range) 20-64 19-62
Weight (Mean) 164.79 ± 29.05 158.29 ± 33.71 0.341
Weight (Range) 114.8-222.0 110.0-235.0
BMI (Mean) 27 ± 4.11 25.8 ± 4 0.165
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possible, both within groups and between groups. A
paired sample t-test was used to assess changes over
time for each group. All data elements were screened for
reasonableness, and all missing, suspicious, or impos-
sible values were referred back to the monitoring team
for query generation and resolution. All numerical vari-
ables were tested for normality, and data found to be
substantially non-normally distributed were analyzed by
appropriate nonparametric methods. Numerical variables
were summarized as the number of subjects, mean, stand-
ard deviation, and significance. Categorical variables were
summarized as counts and percentages. Data were derived
from diary entries, clinical assessments, questionnaires,
and other relevant assessments at postbaseline measure-
ment points.
An interim analysis on the primary endpoint was
performed after the completion of the first 50 subjects. It
was determined that additional subjects would be neces-
sary to reach statistical significance. All study and data
personnel remained blinded until the conclusion of the
analysis, at which point only the statistician was un-
blinded. The efficacy of test products was evaluated with
respect to stool form, bowel urgency, abdominal bloating,
abdominal discomfort or pain, satisfaction with bowel
habits, flatulence, and burping. Summary statistics
(n, mean, standard deviation (SD) and standard error (SE)
means) were presented for each of these numeric second-
ary outcome variables by product. Paired t-tests were
employed to check for any difference between baseline
and each assessment time point in these parameters. Inde-
pendent t-test was employed to assess the efficacy of
the products.
Excel 2003 (Microsoft Corp., Redmond, WA) was used
for data entry, validation, restructuring, calculating
changes in variables over time, reorganizing and reformat-
ting results, and preparing graphs. Statistical analyses
(descriptive statistics and Student’s t-tests) were performed
using SPSS Base System ver. 19 (IBM SPSS Inc., Chicago,
IL). Data were analyzed between groups using independ-
ent sample t-tests to determine the change from baseline.
Statistical analyses were performed using SPSS Base
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One hundred thirty-eight subjects were screened to take
part in this study. Of these, 87 were randomized to pla-
cebo (n = 44) and product (n = 43). There were four with-
drawals in the active group and one in the placebo group.
These five patients were lost to follow-up (the patients
failed to show for visits). Therefore, the results provided
are for 82 subjects. The demographics and baseline char-
acteristics are shown in Table 1.There were no significant differences in body
temperature, diastolic blood pressure, pulse, or respiratory
rate between groups or compared with baseline. Systolic
blood pressure was statistically but not clinically signifi-
cant different between groups at visit 3 (115.10 mmHg in
the active group vs. 122.34 mmHg in the placebo group
(p = 0.02)). There were no significant differences in weight
between groups at any time point (p > 0.05). BMI was sig-
nificantly lower in the treatment group at week 4 com-
pared to the placebo group (25.36 kg/m2 vs. 27.23 kg/m2,
p = 0.037), with no significant changes compared to base-
line in either group (p > 0.05).
The primary endpoint of this study was bowel move-
ment frequency. The numbers of spontaneous bowel
movements and complete spontaneous bowel movements
were investigated. The subjects in the active group dem-
onstrated significant increases in number of spontaneous
bowel movements (SBM) at week 1 (p = 0.001), week 2
(p = 0.001), week 3 (p = 0.000), and week 4 (p = 0.000)
compared to baseline. In addition, the SBM endpoint
demonstrated nearly significant and significant differences
between the active and the placebo group at week 2
Table 2 Effect of treatment on daily bowel movement frequency (Spontaneous Bowel Movements)
Baseline (mean ± SE) Week 1 (mean ± SE) Week 2 (mean ± SE) Week 3 (mean ± SE) Week 4 (mean ± SE)
Placebo 0.35 ± 0.012 0.49 ± 0.035 0.50 ± 0.039 0.47 ± 0.026 0.51 ± 0.029
Kivia powder 0.34 ± 0.012 0.51 ± 0.044 0.61 ± 0.043 0.70 ± 0.054a 0.62 ± 0.038b
ap ≤ 0.01 vs. placebo at this time point.
bp ≤ 0.05 vs. placebo at this time point.
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(Table 2, Figure 2). The changes in SBM from baseline to
week 3 (p = 0.000) and from baseline to week 4 (p = 0.019)
were significantly higher in the treatment group compared
to the placebo group. Significant increases in number of
complete spontaneous bowel movements (CSBM) were ob-
served at week 1 (p = 0.000), week 2 (p = 0.000), week 3
(p = 0.000), and week 4 (p = 0.000) compared to baseline.
Moreover, CSBM was significantly higher for active group
compared to placebo at week 2 (p = 0.001) (Table 3,
Figure 3). The change in daily average of CSBM from base-
line to week 2 (p = 0.004) was significantly higher in the
treatment group compared to the placebo group.
The secondary objective of this study was to determine
the efficacy of Kivia powder on gut health compared to
placebo. There were nearly significant and significant de-
creases in abdominal bloating at week 1 (p = 0.095), week
2 (p = 0.003), week 3 (p = 0.002), week 4 (p = 0.004) com-
pared to baseline. Significant and nearly significant reduc-
tions in abdominal discomfort or pain were observed at
week 2 (p = 0.059) and week 4 (p = 0.018) compared to
baseline. Moreover, abdominal discomfort or pain was
lower for the treatment group compared to placebo at
week 1 (p = 0.044) and week 3 (p = 0.026) (Figure 4). There
were significant increases in satisfaction with bowel habits
at week 1 (p = 0.001), week 2 (p = 0.000), week 3






























Figure 2 Comparison of Kivia powder and placebo in spontaneous bo
higher for Kivia Powder group compared to placebo group at week 3 andThere was no significant difference between groups in
terms of abdominal bloating and satisfaction with bowel
habits.
Flatulence was significantly lower for active group
compared to placebo at week 2 (p = 0.047) and week 3
(p = 0.023) (Figure 5). Burping demonstrated nearly sig-
nificant difference between the active and the placebo
group at week 4 (p = 0.079).
Bowel movement associated with urgency was reduced in
the treatment group compared to the placebo group from
weeks 1 to 4. The percent reduction in bowel urgency in
the active group compared to the placebo group at weeks
1, 2, 3, and 4 were −26%, -25%, -32%, and −26%, respect-
ively. The number of bowel movements associated with ur-
gency was significantly lower in the treatment group
compared to the placebo group at week 3 (p = 0.048).
Moreover, the number of bowel movements associated
with urgency decreased from baseline to week 1 (p = 0.040)
and to week 3 (p = 0.024) in the treatment group, while
the placebo group did not report any reductions in
bowel urgency.
In terms of stool forms, there was a reduction in stool
forms 1 and 2 and an increase in stool forms 3, 4, and 5 in
both groups. Between-group comparisons demonstrated
that by week 2, there were significantly more type 4 bowel
movements (sausage-shaped and smooth) in the Kivia







wel movement. Spontaneous bowel movement was significantly
week 4.
Table 3 Effect of treatment on daily bowel movement frequency (Complete Spontaneous Bowel Movements)
Baseline (mean ± SE) Week 1 (mean ± SE) Week 2 (mean ± SE) Week 3 (mean ± SE) Week 4 (mean ± SE)
Placebo 0.07 ± 0.016 0.27 ± 0.046 0.35 ± 0.063 0.37 ± 0.059 0.37 ± 0.055
Kivia powder 0.10 ± 0.020 0.33 ± 0.044 0.61 ± 0.043a 0.47 ± 0.051 0.42 ± 0.057
ap≤0.01 vs. placebo at this time point.
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movements (soft blobs with clear-cut edges) in the treat-
ment group compared to the placebo group (p = 0.041).
There were no serious adverse events reported in this
study. There were a total of eight adverse events. Seven of
the eight adverse events occurred in the treatment group.
Five of the seven adverse events in the treatment group
were considered as being possibly related to the treatment,
and these included flatulence (MedDRA diagnosis code
10016766; n = 3) and bloating (MedDRA diagnosis code
10005265; n = 2). These adverse events resolved spontan-
eously without treatment.Discussion
In this study, an extract of kiwifruit (Kivia powder)
containing Zyactinase™ was investigated for its ability to
improve bowel function and satisfaction in subjects with
occasional constipation. Bowel function was determined
using various endpoints, including the number of bowel
movements, and bowel health was based on endpoints
such as satisfaction, abdominal bloating and discomfort,
burping, and flatulence. Improvements were noted in
the number of bowel movements, with increased bowel
movements in the group using the studied extract. There
were also improvements observed in bowel health andFigure 3 Comparison of Kivia powder and placebo in complete spont
was significantly higher for Kivia Powder group compared to placebo groustool formation. This suggests that Kivia powder im-
proved bowel habits in this group of subjects.
Chronic constipation is often dealt with by a physician
with recommendations for over-the-counter medications
such as bulk-forming laxatives, stimulants, stool soft-
eners, lubricants, or osmotics. Although individuals suf-
fering from occasional constipation also have access to
and use these agents, with or without knowledge of their
physicians, many individuals might prefer the option of
an effective natural agent for occasional use. Given the
high costs associated with the diagnosis and treatment
of constipation [5] in conjunction with considerable
prevalence rates noted in the literature [4], it is clear that
these products would be of interest to consumers. High-
fiber food products and supplements containing psyl-
lium or flax, as well as aloe and probiotics, are sold and
used for this purpose and have been investigated in clin-
ical trials [6-8]. Kivia powder containing Zyactinase™ is a
freeze-dried powder from kiwifruit (Actinidia deliciosa
var. deliciosa (C.F. Liang and A.R. Ferguson), containing
the enzyme actinidin, plant polyphenols, dietary fiber,
carbohydrates, and oligosaccharides. Although the po-
tential mechanism of action for its anticonstipative ef-
fects are not yet completely clear, kiwifruit extract is rich
in enzymes able to aid in digestion, such as actinidin, as
well as oligosaccharides, which may act as prebiotics,aneous bowel movement. Complete spontaneous bowel movement
p at week 2.
Figure 4 Comparison of Kivia powder and placebo in abdominal discomfort. Abdominal Discomfort was significantly lower for Kivia Powder
group compared to placebo group at week 1 and week 3.
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gastrointestinal tract. Additionally, in vitro, Zyactinase™
significantly increased the growth of the probiotic bac-
teria Lactobacillus reuteri, Lactobacillus acidophilus,
Pediococcus acidilactici, and Lactobacillus planetarium,
further supporting its prebiotic role in the gut [18]. In
this study Kivia aided gentle laxation without urgency
whilst promoting normal stool formation, making the
product ideally suited as an over the counter medication
for occasional constipation.
Although strong published human and animal data are
lacking at this time, unpublished data suggest that use of
the fruit decreased constipation in elderly patients in
New Zealand. Also, in an earlier clinical study, Kivia was
found to promote bowel movement, improve discomfortFigure 5 Comparison of Kivia powder and placebo in flatulence. Flatu
placebo group at week 2 and week 3.in the abdomen, and improve quality of life in elderly
patients in Japan [9]. Like the study by Uebaba et al., our
study also suggests improvement in the number of
bowel movements. Further research is required in order
to compare our results with those of others.
The main endpoints of this study included the number
of spontaneous and complete spontaneous bowel move-
ments. Both spontaneous and complete spontaneous
bowel movement frequency increased between groups and
compared to baseline and these improvements are likely
due to the multiple effects of the extract on bowel health
as described above. Secondary endpoints of this study in-
cluded abdominal bloating, abdominal discomfort or pain,
satisfaction with bowel habits, flatulence, burping, stool
form and bowel urgency. Abdominal bloating, abdominallence was significantly lower for Kivia Powder group compared to
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onstrated significant decreases from baseline. In addition,
abdominal pain or discomfort and flatulence were signifi-
cantly lower in the treatment group than in the placebo
group. Stool form was also improved as proven by the de-
crease in stool form 1 and 2, which are characteristic stool
of people with constipation, and an increase in stool form
3 and 4, the optimal stool form, in the treatment group.
These results suggest that Kivia may be of assistance in
other gut conditions related to these secondary gut health
parameters such as irritable bowel syndrome and chronic
constipation, but that will require further study.
Regarding within group change over time, satisfaction
and abdominal bloating did not improve significantly in
either group. However, abdominal bloating steadily de-
creased and satisfaction steadily increased in both groups
nonsignificantly with time. This suggests that taking part
in the study itself may have allowed for some placebo-
related benefits and that additional benefits of the product
were not obvious. Also, expectations play a role in satisfac-
tion, and the expectations of the study product may have
been high. It is interesting to note the strong placebo ef-
fect so often reported with gut health studies and that not
only did bowel movements increase but also that the stool
features also improved in the placebo group albeit not as
much as the active group
Bowel movement frequency is an objective endpoint
and easily quantified compared to subjective feelings of as-
sociated symptoms. It is a common misconception that
normal bowel habits involve daily excretion [5] and this
misconception may have contributed to a lack of improve-
ment in satisfaction despite increased bowel movements.
Furthermore, since subjects were not screened and
selected based on secondary gut health parameters, vari-
ability within our sample along these endpoints would
have contributed to decreased room for improvement thus
any improvement is noteworthy and lends credence to
further exploration.
Another limitation of this study was that the subjects
were not specifically chosen based on gut health parame-
ters such as bloating, pain, and flatulence. Given that these
symptoms are also associated with irritable bowel syn-
drome, future studies should screen for these symptoms
and only subjects with certain levels of these symptoms
should be included. Thus, further research is required to
evaluate the impact of the Kivia powder product on a
population of subjects who would be specifically selected
for their baseline level of other gut health parameters
(bloating, pain, flatulence, burping, etc.) to determine the
true impact of the product on these symptoms.
In conclusion, this proprietary extract of kiwifruit,
containing Zyactinase™, significantly increased the num-
ber of spontaneous and complete spontaneous bowel
movements after four weeks when compared to placebo.Gut health parameters associated to constipation also im-
proved from baseline and within groups. In addition, the
product was well tolerated at the daily-administered dose
of one sachet (containing 5,500 mg of Zyactinase™). Also,
the decreased use of rescue medication in the treatment
group, already lower than in the placebo group at baseline,
suggests that the product was helpful in this group of indi-
viduals. The results of this study suggest that this product
may be of interest to generally healthy adults with occa-
sional constipation and associated abdominal discomfort.
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